Showing 2251-2260 of 5623 results for "".
- The International Agency for the Prevention of Blindness (IAPB) Welcomes Over 300 International Delegates to Singaporehttps://modernod.com/news/the-international-agency-for-the-prevention-of-blindness-iapb-welcomes-over-300-international-delegates-to-singapore/2481690/The International Agency for the Prevention of Blindness (IAPB) has welcomed more than 300 delegates to Singapore for its "2030 IN SIGHT LIVE" event. Hosted in partnership with the Singapore Eye Research Institute (SERI), the event gathers experts and thought leaders from eye
- FDA Clearance Expands the Label of Eyenuk's EyeArt AI System for the Detection of DRhttps://modernod.com/news/fda-clearance-expands-the-label-of-eyenuks-eyeart-ai-system-for-the-detection-of-dr/2481685/Eyenuk has received FDA clearance to use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy (DR), adding to the already-cleared usage with Canon CR-2 AF and Canon CR-2 Plus AF cameras. The regulatory clearance of t
- iSTAR Medical to Present New 3-Year STAR-GLOBAL Data at World Glaucoma Congresshttps://modernod.com/news/istar-medical-to-present-new-3-year-star-global-data-at-world-glaucoma-congress/2481683/iSTAR Medical announced that it will be hosting a symposium where it will present 3-year interim data from the STAR-GLOBAL trial and will also be running a dry lab at its booth at the 10th World Glaucoma Congress (WGC) taking place in Rome, Italy from June 28 to July 1, 2023.
- New Analysis From N-MOmentum Clinical Trial of Uplinza Demonstrate Process that Could Improve Clinical Care Process for NMOSDhttps://modernod.com/news/new-analysis-from-n-momentum-clinical-trial-of-uplinza-demonstrate-process-that-could-improve-clinical-care-process-for-nmosd/2481680/Horizon Therapeutics announced the publication of a new analysis from the N-MOmentum clinical trial of Uplinza demonstrating the utility of an adjudication process that could improve clinical care decision-making in neuromyelitis optica spectrum disorder (NMOSD) through more accurate and consiste
- Study: Lab-Grown ‘Mini-Corneas’ Mimic Developing Human Corneashttps://modernod.com/news/study-lab-grown-mini-corneas-mimic-developing-human-corneas/2481678/Researchers at NYU Langone Health say three-dimensional, lab-grown “mini-corneas” resemble the developing human cornea, potentially making them a new tool for the study of corneal diseases. P
- Beacon Therapeutics Launches with Goal of Developing Gene Therapies for Retinal Diseaseshttps://modernod.com/news/beacon-therapeutics-launches-with-goal-of-developing-gene-therapies-for-retinal-diseases/2481673/Beacon Therapeutics has launched and will develop a new generation of gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness. Syncona Limited, with additional investors including OSE, has provided £96 million ($120 million) to fund the acqu
- FDA Clears CorNeat EverPatch, World's First Non-Degradable, Synthetic Tissue Substitute for Ophthalmic Surgeryhttps://modernod.com/news/fda-clears-corneat-everpatch-worlds-first-non-degradable-synthetic-tissue-substitute-for-ophthalmic-surgery/2481668/The FDA has granted 510(k) clearance to CorNeat Vision's EverPatch, which the company describes as the first synthetic, non-degradable tissue-integrating matrix for use in ophthalmic surgeries. It is composed of a non-woven, polymer matrix which integrates with surrounding tissue an
- Yuyu Pharma Announces Topline Results from the ICECAP Phase 1/2 Trial of YP-P10 in Dry Eye Diseasehttps://modernod.com/news/yuyu-pharma-announces-topline-results-from-the-icecap-phase-12-trial-of-yp-p10-in-dry-eye-disease/2481651/Yuyu Pharma announced topline results from the ICECAP phase 1/2 trial of YP-P10 in patients with dry eye disease. ICECAP was the first human, signal-seeking, phase 1/2 trial evaluating the safety and efficacy of YP-P10 over 12 weeks (85 days) of treatment in subjects with dry eye disease, ac
- AI Used to Advance Drug Delivery System for Glaucoma and Other Chronic Diseaseshttps://modernod.com/news/ai-used-to-advance-drug-delivery-system-for-glaucoma-and-other-chronic-diseases/2481636/Researchers from Wilmer Eye Institute, Johns Hopkins Medicine say they have used artificial intelligence models and machine-learning algorithms to successfully predict which components of amino acids that make up therapeutic proteins are most likely to safely deliver therapeutic drugs to animal e
- Sight Sciences: Two Year Study Results Show Sustained Reductions in IOP and Glaucoma Medication Use with Omni Treatmenthttps://modernod.com/news/sight-sciences-two-year-study-results-show-sustained-reductions-in-iop-and-glaucoma-medication-use-in-mild-moderate-poag-patients-treated-with-omni/2481630/Sight Sciences announced the publication of 2-year results of the ROMEO (Retrospective, Observational, Multicenter, Evaluation of OMNI) study in Clinical Ophthalmology. The longest multicenter study of the Omni Surgical System technology to date in both standalone and comb